A new approach

CY-101 helps the immune system to fight cancer by exposing tumor neoantigens and inhibiting mechanisms that drive tumor growth and immune evasion.

CY-101 helps the immune system to fight cancer by exposing tumor neoantigens and inhibiting mechanisms that drive tumor growth and immune evasion.

Pipeline

AGENT: CY-101 // MONOTHERAPY | ADRENOCORTICAL CARCINOMA | PH II

STATUS: Initiate 2H-25 | SPONSOR: CRUK

AGENT: CY-101 // CY-101 + PEMBROLIZUMAB | COLORECTAL CANCER | PH I/II

STATUS: Initiate 1H-26 | SPONSOR: Cytovation

AGENT: CY-101 // MONOTHERAPY | ALL COMERS | Ph I/II

STATUS: Completed | SPONSOR: Cytovation

AGENT: CY-101 // MONOTHERAPY | LIVER | Ph I

STATUS: Completed | SPONSOR: Cytovation

AGENT: CY-101 + Pembrolizumab // COMBINATION | ALL COMERS | Ph I

STATUS: Completed | SPONSOR: Cytovation | COLLABORATOR: Merck

AGENT: CY-101 // MONOTHERAPY | ADRENOCORTICAL CARCINOMA | PH II

STATUS: Initiate 2H-25 | SPONSOR: CRUK

AGENT: CY-101 // CY-101 + PEMBROLIZUMAB | COLORECTAL CANCER | PH I/II

STATUS: Initiate 1H-26 | SPONSOR: Cytovation

AGENT: CY-101 // MONOTHERAPY | ALL COMERS | Ph I/II

STATUS: Completed | SPONSOR: Cytovation

AGENT: CY-101 // MONOTHERAPY | LIVER | Ph I

STATUS: Completed | SPONSOR: Cytovation

AGENT: CY-101 + Pembrolizumab // COMBINATION | ALL COMERS | Ph I

STATUS: Completed | SPONSOR: Cytovation | COLLABORATOR: Merck